Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Easywell Biomedicals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 2,040.45%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Easywell Biomedicals's 3-Year ROIIC % or its related term are showing as below:
ROCO:1799's 3-Year ROIIC % is ranked better than 99.47% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.61
vs ROCO:1799: 2040.45
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Easywell Biomedicals 3-Year ROIIC % Related Terms
Easywell Biomedicals 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Easywell Biomedicals's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Easywell Biomedicals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Easywell Biomedicals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Easywell Biomedicals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Easywell Biomedicals's 3-Year ROIIC % falls into.
Easywell Biomedicals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -69.846 (Dec. 2025) - -161.258 (Dec. 2022) )
/
( 820.251 (Dec. 2025) - 815.771 (Dec. 2022) )
=
91.412
/
4.48
=
2,040.45%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Easywell Biomedicals (ROCO:1799) has a 3-Year ROIIC % of 2,040.45 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Easywell Biomedicals and its competitors. According to the industry distribution chart, Easywell Biomedicals ranks #5 out of 946 companies in the Drug Manufacturers industry, placing it in the top 0.5%.
Is Easywell Biomedicals' 3-Year ROIIC % too high?
Easywell Biomedicals' current 3-Year ROIIC % is 2,040.45. The Drug Manufacturers industry median 3-Year ROIIC % is 3.61. Easywell Biomedicals' value of 2,040.45 is 56422.2% above this industry median. Based on the distribution chart, Easywell Biomedicals ranks #5 out of 946 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Easywell Biomedicals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Easywell Biomedicals ranks #5 out of 946 companies for 3-Year ROIIC %. This places Easywell Biomedicals in the top 1% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.61. Easywell Biomedicals' value of 2,040.45 is 56422.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.61, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Easywell Biomedicals's current 3-Year ROIIC % of 2,040.45 is 56422.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Easywell Biomedicals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Easywell Biomedicals's current 3-Year ROIIC % is 2,040.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$82.98, compared to a current price of NT$31.65 — trading 61.9% below its estimated fair value. The current 3-Year ROIIC % is 2,040.45 and 56422.2% above the Drug Manufacturers industry median of 3.61. Easywell Biomedicals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current 3-Year ROIIC % is 2,040.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?
Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued.
The current stock price of NT$31.65 is trading 61.9% below its estimated GF Value™ of NT$82.98.
GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.
Key valuation signals for ROCO:1799:
3-Year ROIIC %: 2,040.45
GF Value™: NT$82.98 vs. price of NT$31.65 (61.9% below fair value)
Industry Position: 56422.2% above the Drug Manufacturers median (#5 of 946)
No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
55GF Score
Get the complete analysis for ROCO:1799
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1799 has been successfully added to your 
